McClellan Leaves For CMS As Crawford Heads Reorganized FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA Commissioner Mark McClellan, MD/PhD, is leaving FDA before the agency makes a decision on whether Barr Labs' Plan B (levenorgestrel .75 mg) is approvable for over-the-counter use
You may also be interested in...
FDA Commissioner Confirmation Clears The Way For Personnel Changes
The confirmation of FDA Commissioner Lester Crawford will allow for a reorganization of upper level management at the agency
FDA Commissioner Confirmation Clears The Way For Personnel Changes
The confirmation of FDA Commissioner Lester Crawford will allow for a reorganization of upper level management at the agency
FDA Commissioner Confirmation Clears The Way For Personnel Changes
The confirmation of FDA Commissioner Lester Crawford will allow for a reorganization of upper level management at the agency